Prognostic capacity of preoperative levels of selected blood inflammatory markers for glioma patient’s survival

dc.contributor.authorYelaman, Konysbek
dc.date.accessioned2018-06-04T09:13:15Z
dc.date.available2018-06-04T09:13:15Z
dc.date.issued2018-05
dc.description.abstractGlioma is considered to be a rare type of cancer of the central nervous system (CNS) with the average age-adjusted incidence rate of 3.4 per 100, 000 population. Moreover, gliomas are the most common type of malignant brain tumors among adult population. They account for about 80% of all diagnosed brain tumors originating from brain parenchyma. Despite achievements in medical treatment and technologies glioblastoma patients still have poor prognosis with 3-5% of surviving patients after 12-15 months following standard therapy. In addition, recent studies highlight importance of blood, and molecular markers in predicting presence of gliomas.en_US
dc.identifier.citationYelaman, Konysbek. (2018) Prognostic capacity of preoperative levels of selected blood inflammatory markers for glioma patient’s survival. Nazarbayev University School of Medicineen_US
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/3292
dc.language.isoenen_US
dc.publisherNazarbayev University School of Medicineen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectVascular endothelial growth factoren_US
dc.subjectIsocitrate dehydrogenaseen_US
dc.subjectGliomaen_US
dc.subjectcentral nervous systemen_US
dc.titlePrognostic capacity of preoperative levels of selected blood inflammatory markers for glioma patient’s survivalen_US
dc.typeMaster's thesisen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Analysis of glioma patient's survival.pdf
Size:
308.12 KB
Format:
Adobe Portable Document Format
Description:
Thesis
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6 KB
Format:
Item-specific license agreed upon to submission
Description: